Platelet-Lymphocyte Ratio, Circulating Tumor Cells and Circulating Tumor Microemboli as Predictors of Thrombosis in Patients with Gastric Cancer

A B S T R A C T

Background: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ratio (PLR) may predispose to VTE.
Objective: To evaluate correlations of CTCs, CTM, and PLR with VTE and progression-free survival (PFS) in gastric cancer patients.
Methods: Patients with gastric cancer were recruited (March 2016 to April 2017). CTCs were assayed by ISET at two timepoints: before neoadjuvant treatment (CTC1) and after surgery/before adjuvant therapy (CTC2) for patients with localized disease, and before first-line chemotherapy (CTC1) and after 6 months (CTC2) for patients with metastases. VTE incidence was determined retrospectively. PFS was estimated by Kaplan-Meier analysis.
Results: We studied 93 patients. According to Khorana scores, 63 (67.7%) patients were at intermediate and 30 (32.3%) were at high risk for VTE. VTE incidence was 20.4% and CTM were found in 39.8%. VTE developed in 7/37 (18.9%) CTM-positive and in 11/50 (22%) CTM-negative patients (p=0.93). When PLR >288, VTE occurred in 7/14 patients (p=0.005). PLR also associated with poor PFS (p<0.0001). CTC2 was associated with poor PFS (p<0.0001). CTC2, PLR and VTE were independent prognostic factors for PFS (p=0.005, 0.043, and <0.0001 respectively).
Conclusion: PLR is a prognostic indicator for PFS and for VTE in gastric cancer. Neither CTC, nor CTM improved risk stratification for VTE in our population.

Keywords

Circulating tumor cells, circulating tumor microemboli, thrombosis, gastric cancer



Get access to the full version of this article.

Article Info

Article Type
Research Article
Publication history
Received: Wed 01, Sep 2021
Accepted: Tue 14, Sep 2021
Published: Wed 29, Sep 2021
Copyright
© 2023 Bruno Soriano Pignataro. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2021.10.01

Author Info

Corresponding Author
Bruno Soriano Pignataro
Departament of Vascular and Endovascular Surgery, A.C. Camargo Cancer Center, Sao Paulo, Brazil

Figures & Tables



Get access to the full version of this article.

References

1.     Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5: 632-634. [Crossref]

2.     Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM et al. (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160: 809-815. [Crossref]

3.     Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41: 3-14. [Crossref]

4.     Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM et al. (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158: 585-593. [Crossref]

5.     Khorana AA, Francis CW (2018) Risk prediction of cancer-associated thrombosis : Appraising the first decade and developing the future. Thromb Res 164: S70-S76. [Crossref]

6.     Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111: 4902-4907. [Crossref]

7.     Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7: 291-292. [Crossref]

8.     Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R et al. (2010) Prediction of venous thromboembolism in cancer patients. Blood 116: 5377-5382. [Crossref]

9.     Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. [Crossref]

10.  Abdallah EA, Braun AC, Flores BCTCP, Senda L, Urvanegia AC et al. (2019) The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer. Oncologist 24: e854-e863. [Crossref]

11.  Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A et al. (2015) The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol 308: C229-C236. [Crossref]

12.  Mego M, De Giorgi U, Broglio K, Dawood S, Valero V et al. (2009) Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 101: 1813-1816. [Crossref]

13.  Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I et al. (2017) Circulating tumor cell count and thrombosis in metastatic breast cancer. J Thromb Haemost 15: 1981-1988. [Crossref]

14.  Bystricky B, Reuben JM, Mego M (2017) Circulating tumor cells and coagulation - Minireview. Crit Rev Oncol Hematol 114: 33-42. [Crossref]

15.  Tormoen GW, Haley KM, Levine RL, McCarty OJT (2012) Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol 2: 115. [Crossref]

16.  Yüksel M, Yıldız A, Oylumlu M, Akyüz A, Aydın M et al. (2015) The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol 15: 640-647. [Crossref]

17.  Hudzik B, Szkodzinski J, Gorol J, Niedziela J, Lekston A et al. (2015) Platelet-to-lymphocyte ratio is a marker of poor prognosis in patients with diabetes mellitus and ST-elevation myocardial infarction. Biomark Med 9: 199-207. [Crossref]

18.  Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L et al. (2015) Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 136: 1234-1240. [Crossref]

19.  Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G et al. (2014) Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res 24: 40-46. [Crossref]

20.  Lee KW, Bang SM, Kim S, Lee HJ, Shin DY et al. (2010) The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 8: 540-547. [Crossref]

21.  Khorana AA (2018) Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet Haematol 5: e273-e274. [Crossref]

22.  Carrier M, Abou Nassar K, Mallick R, Tagalakis V, Shivakumar S et al. (2019) Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 380: 711-719. [Crossref]

23.  Khorana AA, Soff GA, Kakkar AK, Vadhan Raj S, Riess H et al. (2019) Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 380: 720-728. [Crossref]

24.  Khorana AA, Noble S, Lee AYY, Soff G, Meyer G (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism : guidance from the SSC of the ISTH. J Thromb Haemost 16: 1891-1894. [Crossref]

25. Ay C, Pabinger I, Cohen AT (2017) Cancer-associated venous thromboembolism : Burden , mechanisms , and management. Thromb Haemost 117: 219-230. [Crossref]